You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《業績》百時美施貴寶(BMY.US)季績勝預期 惟股價仍跌5.8%
美國藥廠百時美施貴寶(BMY.US)公布第二季業績。季度純利按年跌22%至13.1億美元,每股季度攤薄純利64美仙,經調整後為1.46美元。季度收入按年升1%至122.69億美元,高於市場預期的114億美元。 與輝瑞共享藥物凝血通(Eliquis)季度銷售按年升8%至37億美元,癌症免疫藥Opdivo季度銷售按年升7%至26億美元,失去專利權保護的骨髓病變藥物Revlimid季度銷售按年跌38%至8.38億美元,三者均高於市場預期。 百時美施貴寶股價昨日(31日)跌5.8%,報43.31美元。市場關注公司未來新藥前景。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account